How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle

Eli Lilly's CEO, Dave Ricks, is tackling the industry's notorious boom-bust cycle by focusing on sustainable practices and innovative solutions to address public skepticism and high drug prices. As the 11th CEO in the company's long history, Ricks aims to improve the industry's reputation and ensure affordability, especially in light of reports showing that high costs are forcing some diabetics to limit their insulin intake. His strategies are crucial for the future of pharmaceutical companies, aiming to balance profitability with public trust and accessibility.